top of page
  • ODI Pharma

ODI Pharma AB approves the official launch of kandol., an exclusive CBD infused skincare line

ODI Pharma AB (“ODI Pharma” or the “Company”), a producer and representative of finished pharmaceutical cannabis and cosmetics products, now launches kandol., a CBD skincare product line. The products will, as an initial step, be available online at to customers within the EU starting mid-September 2021.

On 14 January 2021, the Company announced its decision to implement a new business area consisting of specialized, highly CBD-infused skincare products (“Project Skin”). After a thorough evaluation of the market and its potential for certain product types, the Company has carried out extensive research on finding the best formulation for the products and ultimately defined a product line which is now produced and launched to the market under the brand “kandol.”. Additionally, ODI Pharma is currently expanding the distribution channels (online and stationary) for the product line and has so far built solid relationships in many European countries.

The product line initially consists of a CBD-infused facial cream, facial mask and body balm. The products contain what the Company describes as the Golden Standard of Cannabidiol (CBD) and are designed to the EU-approved definition of Cannabidiol as an antioxidant, antiseborrheic, skin conditioner and skin protector. The dermatological efficiency tests were run on the facial cream by an independent multinational company specializing in cosmetic testing on 40 test subjects following the EU regulations. Test results have confirmed kandol. as one of the most effective skincare products and prove that the Company has found a disrupting formula that shows outstanding effects. Among other things, the product improves the appearance of the skin and compared with the same type of products used in the past, the tested product was assessed as better than (57%) or comparable with (40%) the best products the test subjects had ever tested before, meaning 97% of test subjects found ODI Pharma’s product better or comparable. Tested effects were amongst others purifying pores, reducing appearance of wrinkles, improving skin condition, giving healthy look, skin smoothening, nourishing, protecting from drying and leaving the skin moisturized improving redness, reducing signs of fatigue and accelerate the disappearance of blemishes.

“After intensive preparation, I’m very excited to update that we are launching kandol. CBD infused luxury skincare line. Initial independent testing confirms our belief of excellence of our products. We are confident that kandol. represents significant growth potential for ODI Pharma and with expected revenues starting in mid-September 2021. We are looking forward to the continued journey of improving life quality by the application of cannabinoids – now also as skincare products.” – says Derek Simmross, CEO.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB


ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis and cosmetics products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.

210817 - ODI launches kandol_vf.docx
PDF herunterladen • 848KB

0 Kommentare

Aktuelle Beiträge

Alle ansehen

ODI Pharma AB: Updated market and business overview

ODI Pharma AB (“ODI” or the “Company”) hereby present an updated overview of its market position and the latest trends observed in the cannabis industry, particularly in Europe. Progress in the cooper

ODI Pharma AB: Publication of half-year report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July – December 2023. The report is available as an attached document to this press release and on the Compa


bottom of page